

Global Drugs for the Treatment of Refractory Gout Market Growth 2024-2030

<https://marketpublishers.com/r/GE52568B6238EN.html>

Date: November 2024

Pages: 121

Price: US\$ 3,660.00 (Single User License)

ID: GE52568B6238EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

Drugs for the treatment of refractory gout encompass a range of therapeutic options aimed at managing severe and persistent symptoms when standard treatments have proven insufficient. Biologic agents, such as interleukin inhibitors, play a crucial role by targeting inflammatory cytokines involved in the pathogenesis of gouty inflammation. Additionally, pegloticase, a recombinant uricase enzyme, is utilized to aggressively lower serum uric acid levels in refractory cases.

The global Drugs for the Treatment of Refractory Gout market size is projected to grow from US\$ million in 2024 to US\$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.

LP Information, Inc. (LPI)'s newest research report, the "Drugs for the Treatment of Refractory Gout Industry Forecast" looks at past sales and reviews total world Drugs for the Treatment of Refractory Gout sales in 2023, providing a comprehensive analysis by region and market sector of projected Drugs for the Treatment of Refractory Gout sales for 2024 through 2030. With Drugs for the Treatment of Refractory Gout sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Drugs for the Treatment of Refractory Gout industry.

This Insight Report provides a comprehensive analysis of the global Drugs for the Treatment of Refractory Gout landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Drugs for the Treatment of Refractory Gout portfolios and capabilities,

market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Drugs for the Treatment of Refractory Gout market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Drugs for the Treatment of Refractory Gout and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Drugs for the Treatment of Refractory Gout.

United States market for Drugs for the Treatment of Refractory Gout is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Drugs for the Treatment of Refractory Gout is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Drugs for the Treatment of Refractory Gout is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Drugs for the Treatment of Refractory Gout players cover Roche, Biogen, Fresenius Kabi, Novartis, Sobi, etc. In terms of revenue, the global two largest companies occupied for a share nearly

% in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Drugs for the Treatment of Refractory Gout market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Interleukin Inhibitors

Tumor Necrosis Factor Inhibitors

PEGylated Recombinant Uricase

Other

Segmentation by Application:

Hospital and Clinic

Retail Pharmacies

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Roche

Biogen

Fresenius Kabi

Novartis

Sobi

Kiniksa Pharmaceuticals

Pfizer

Amgen

Horizon Therapeutics

Qilu Pharmaceutical

Hanwha Chemical

Bio-Thera Solutions

Zhuhai Livzon Biotechnology

Sandoz

Key Questions Addressed in this Report

What is the 10-year outlook for the global Drugs for the Treatment of Refractory Gout market?

What factors are driving Drugs for the Treatment of Refractory Gout market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Drugs for the Treatment of Refractory Gout market opportunities vary by end market size?

How does Drugs for the Treatment of Refractory Gout break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Drugs for the Treatment of Refractory Gout Annual Sales 2019-2030
 - 2.1.2 World Current & Future Analysis for Drugs for the Treatment of Refractory Gout by Geographic Region, 2019, 2023 & 2030
 - 2.1.3 World Current & Future Analysis for Drugs for the Treatment of Refractory Gout by Country/Region, 2019, 2023 & 2030
- 2.2 Drugs for the Treatment of Refractory Gout Segment by Type
 - 2.2.1 Interleukin Inhibitors
 - 2.2.2 Tumor Necrosis Factor Inhibitors
 - 2.2.3 PEGylated Recombinant Uricase
 - 2.2.4 Other
- 2.3 Drugs for the Treatment of Refractory Gout Sales by Type
 - 2.3.1 Global Drugs for the Treatment of Refractory Gout Sales Market Share by Type (2019-2024)
 - 2.3.2 Global Drugs for the Treatment of Refractory Gout Revenue and Market Share by Type (2019-2024)
 - 2.3.3 Global Drugs for the Treatment of Refractory Gout Sale Price by Type (2019-2024)
- 2.4 Drugs for the Treatment of Refractory Gout Segment by Application
 - 2.4.1 Hospital and Clinic
 - 2.4.2 Retail Pharmacies
 - 2.4.3 Other
- 2.5 Drugs for the Treatment of Refractory Gout Sales by Application
 - 2.5.1 Global Drugs for the Treatment of Refractory Gout Sale Market Share by

Application (2019-2024)

2.5.2 Global Drugs for the Treatment of Refractory Gout Revenue and Market Share by Application (2019-2024)

2.5.3 Global Drugs for the Treatment of Refractory Gout Sale Price by Application (2019-2024)

3 GLOBAL BY COMPANY

3.1 Global Drugs for the Treatment of Refractory Gout Breakdown Data by Company

3.1.1 Global Drugs for the Treatment of Refractory Gout Annual Sales by Company (2019-2024)

3.1.2 Global Drugs for the Treatment of Refractory Gout Sales Market Share by Company (2019-2024)

3.2 Global Drugs for the Treatment of Refractory Gout Annual Revenue by Company (2019-2024)

3.2.1 Global Drugs for the Treatment of Refractory Gout Revenue by Company (2019-2024)

3.2.2 Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Company (2019-2024)

3.3 Global Drugs for the Treatment of Refractory Gout Sale Price by Company

3.4 Key Manufacturers Drugs for the Treatment of Refractory Gout Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Drugs for the Treatment of Refractory Gout Product Location Distribution

3.4.2 Players Drugs for the Treatment of Refractory Gout Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR DRUGS FOR THE TREATMENT OF REFRACTORY GOUT BY GEOGRAPHIC REGION

4.1 World Historic Drugs for the Treatment of Refractory Gout Market Size by Geographic Region (2019-2024)

4.1.1 Global Drugs for the Treatment of Refractory Gout Annual Sales by Geographic Region (2019-2024)

4.1.2 Global Drugs for the Treatment of Refractory Gout Annual Revenue by

Geographic Region (2019-2024)

4.2 World Historic Drugs for the Treatment of Refractory Gout Market Size by Country/Region (2019-2024)

4.2.1 Global Drugs for the Treatment of Refractory Gout Annual Sales by Country/Region (2019-2024)

4.2.2 Global Drugs for the Treatment of Refractory Gout Annual Revenue by Country/Region (2019-2024)

4.3 Americas Drugs for the Treatment of Refractory Gout Sales Growth

4.4 APAC Drugs for the Treatment of Refractory Gout Sales Growth

4.5 Europe Drugs for the Treatment of Refractory Gout Sales Growth

4.6 Middle East & Africa Drugs for the Treatment of Refractory Gout Sales Growth

5 AMERICAS

5.1 Americas Drugs for the Treatment of Refractory Gout Sales by Country

5.1.1 Americas Drugs for the Treatment of Refractory Gout Sales by Country (2019-2024)

5.1.2 Americas Drugs for the Treatment of Refractory Gout Revenue by Country (2019-2024)

5.2 Americas Drugs for the Treatment of Refractory Gout Sales by Type (2019-2024)

5.3 Americas Drugs for the Treatment of Refractory Gout Sales by Application (2019-2024)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Drugs for the Treatment of Refractory Gout Sales by Region

6.1.1 APAC Drugs for the Treatment of Refractory Gout Sales by Region (2019-2024)

6.1.2 APAC Drugs for the Treatment of Refractory Gout Revenue by Region (2019-2024)

6.2 APAC Drugs for the Treatment of Refractory Gout Sales by Type (2019-2024)

6.3 APAC Drugs for the Treatment of Refractory Gout Sales by Application (2019-2024)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan

7 EUROPE

- 7.1 Europe Drugs for the Treatment of Refractory Gout by Country
 - 7.1.1 Europe Drugs for the Treatment of Refractory Gout Sales by Country (2019-2024)
 - 7.1.2 Europe Drugs for the Treatment of Refractory Gout Revenue by Country (2019-2024)
- 7.2 Europe Drugs for the Treatment of Refractory Gout Sales by Type (2019-2024)
- 7.3 Europe Drugs for the Treatment of Refractory Gout Sales by Application (2019-2024)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Drugs for the Treatment of Refractory Gout by Country
 - 8.1.1 Middle East & Africa Drugs for the Treatment of Refractory Gout Sales by Country (2019-2024)
 - 8.1.2 Middle East & Africa Drugs for the Treatment of Refractory Gout Revenue by Country (2019-2024)
- 8.2 Middle East & Africa Drugs for the Treatment of Refractory Gout Sales by Type (2019-2024)
- 8.3 Middle East & Africa Drugs for the Treatment of Refractory Gout Sales by Application (2019-2024)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Drugs for the Treatment of Refractory Gout

10.3 Manufacturing Process Analysis of Drugs for the Treatment of Refractory Gout

10.4 Industry Chain Structure of Drugs for the Treatment of Refractory Gout

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Drugs for the Treatment of Refractory Gout Distributors

11.3 Drugs for the Treatment of Refractory Gout Customer

12 WORLD FORECAST REVIEW FOR DRUGS FOR THE TREATMENT OF REFRACTORY GOUT BY GEOGRAPHIC REGION

12.1 Global Drugs for the Treatment of Refractory Gout Market Size Forecast by Region

12.1.1 Global Drugs for the Treatment of Refractory Gout Forecast by Region (2025-2030)

12.1.2 Global Drugs for the Treatment of Refractory Gout Annual Revenue Forecast by Region (2025-2030)

12.2 Americas Forecast by Country (2025-2030)

12.3 APAC Forecast by Region (2025-2030)

12.4 Europe Forecast by Country (2025-2030)

12.5 Middle East & Africa Forecast by Country (2025-2030)

12.6 Global Drugs for the Treatment of Refractory Gout Forecast by Type (2025-2030)

12.7 Global Drugs for the Treatment of Refractory Gout Forecast by Application (2025-2030)

13 KEY PLAYERS ANALYSIS

13.1 Roche

- 13.1.1 Roche Company Information
- 13.1.2 Roche Drugs for the Treatment of Refractory Gout Product Portfolios and Specifications
- 13.1.3 Roche Drugs for the Treatment of Refractory Gout Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.1.4 Roche Main Business Overview
- 13.1.5 Roche Latest Developments
- 13.2 Biogen
 - 13.2.1 Biogen Company Information
 - 13.2.2 Biogen Drugs for the Treatment of Refractory Gout Product Portfolios and Specifications
 - 13.2.3 Biogen Drugs for the Treatment of Refractory Gout Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.2.4 Biogen Main Business Overview
 - 13.2.5 Biogen Latest Developments
- 13.3 Fresenius Kabi
 - 13.3.1 Fresenius Kabi Company Information
 - 13.3.2 Fresenius Kabi Drugs for the Treatment of Refractory Gout Product Portfolios and Specifications
 - 13.3.3 Fresenius Kabi Drugs for the Treatment of Refractory Gout Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.3.4 Fresenius Kabi Main Business Overview
 - 13.3.5 Fresenius Kabi Latest Developments
- 13.4 Novartis
 - 13.4.1 Novartis Company Information
 - 13.4.2 Novartis Drugs for the Treatment of Refractory Gout Product Portfolios and Specifications
 - 13.4.3 Novartis Drugs for the Treatment of Refractory Gout Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.4.4 Novartis Main Business Overview
 - 13.4.5 Novartis Latest Developments
- 13.5 Sobi
 - 13.5.1 Sobi Company Information
 - 13.5.2 Sobi Drugs for the Treatment of Refractory Gout Product Portfolios and Specifications
 - 13.5.3 Sobi Drugs for the Treatment of Refractory Gout Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.5.4 Sobi Main Business Overview
 - 13.5.5 Sobi Latest Developments

13.6 Kiniksa Pharmaceuticals

13.6.1 Kiniksa Pharmaceuticals Company Information

13.6.2 Kiniksa Pharmaceuticals Drugs for the Treatment of Refractory Gout Product Portfolios and Specifications

13.6.3 Kiniksa Pharmaceuticals Drugs for the Treatment of Refractory Gout Sales, Revenue, Price and Gross Margin (2019-2024)

13.6.4 Kiniksa Pharmaceuticals Main Business Overview

13.6.5 Kiniksa Pharmaceuticals Latest Developments

13.7 Pfizer

13.7.1 Pfizer Company Information

13.7.2 Pfizer Drugs for the Treatment of Refractory Gout Product Portfolios and Specifications

13.7.3 Pfizer Drugs for the Treatment of Refractory Gout Sales, Revenue, Price and Gross Margin (2019-2024)

13.7.4 Pfizer Main Business Overview

13.7.5 Pfizer Latest Developments

13.8 Amgen

13.8.1 Amgen Company Information

13.8.2 Amgen Drugs for the Treatment of Refractory Gout Product Portfolios and Specifications

13.8.3 Amgen Drugs for the Treatment of Refractory Gout Sales, Revenue, Price and Gross Margin (2019-2024)

13.8.4 Amgen Main Business Overview

13.8.5 Amgen Latest Developments

13.9 Horizon Therapeutics

13.9.1 Horizon Therapeutics Company Information

13.9.2 Horizon Therapeutics Drugs for the Treatment of Refractory Gout Product Portfolios and Specifications

13.9.3 Horizon Therapeutics Drugs for the Treatment of Refractory Gout Sales, Revenue, Price and Gross Margin (2019-2024)

13.9.4 Horizon Therapeutics Main Business Overview

13.9.5 Horizon Therapeutics Latest Developments

13.10 Qilu Pharmaceutical

13.10.1 Qilu Pharmaceutical Company Information

13.10.2 Qilu Pharmaceutical Drugs for the Treatment of Refractory Gout Product Portfolios and Specifications

13.10.3 Qilu Pharmaceutical Drugs for the Treatment of Refractory Gout Sales, Revenue, Price and Gross Margin (2019-2024)

13.10.4 Qilu Pharmaceutical Main Business Overview

- 13.10.5 Qilu Pharmaceutical Latest Developments
- 13.11 Hanwha Chemical
 - 13.11.1 Hanwha Chemical Company Information
 - 13.11.2 Hanwha Chemical Drugs for the Treatment of Refractory Gout Product Portfolios and Specifications
 - 13.11.3 Hanwha Chemical Drugs for the Treatment of Refractory Gout Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.11.4 Hanwha Chemical Main Business Overview
 - 13.11.5 Hanwha Chemical Latest Developments
- 13.12 Bio-Thera Solutions
 - 13.12.1 Bio-Thera Solutions Company Information
 - 13.12.2 Bio-Thera Solutions Drugs for the Treatment of Refractory Gout Product Portfolios and Specifications
 - 13.12.3 Bio-Thera Solutions Drugs for the Treatment of Refractory Gout Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.12.4 Bio-Thera Solutions Main Business Overview
 - 13.12.5 Bio-Thera Solutions Latest Developments
- 13.13 Zhuhai Livzon Biotechnology
 - 13.13.1 Zhuhai Livzon Biotechnology Company Information
 - 13.13.2 Zhuhai Livzon Biotechnology Drugs for the Treatment of Refractory Gout Product Portfolios and Specifications
 - 13.13.3 Zhuhai Livzon Biotechnology Drugs for the Treatment of Refractory Gout Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.13.4 Zhuhai Livzon Biotechnology Main Business Overview
 - 13.13.5 Zhuhai Livzon Biotechnology Latest Developments
- 13.14 Sandoz
 - 13.14.1 Sandoz Company Information
 - 13.14.2 Sandoz Drugs for the Treatment of Refractory Gout Product Portfolios and Specifications
 - 13.14.3 Sandoz Drugs for the Treatment of Refractory Gout Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.14.4 Sandoz Main Business Overview
 - 13.14.5 Sandoz Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

LIST OF TABLES

Table 1. Drugs for the Treatment of Refractory Gout Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & (\$ millions)

Table 2. Drugs for the Treatment of Refractory Gout Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & (\$ millions)

Table 3. Major Players of Interleukin Inhibitors

Table 4. Major Players of Tumor Necrosis Factor Inhibitors

Table 5. Major Players of PEGylated Recombinant Uricase

Table 6. Major Players of Other

Table 7. Global Drugs for the Treatment of Refractory Gout Sales by Type (2019-2024) & (K Units)

Table 8. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Type (2019-2024)

Table 9. Global Drugs for the Treatment of Refractory Gout Revenue by Type (2019-2024) & (\$ million)

Table 10. Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Type (2019-2024)

Table 11. Global Drugs for the Treatment of Refractory Gout Sale Price by Type (2019-2024) & (US\$/Unit)

Table 12. Global Drugs for the Treatment of Refractory Gout Sale by Application (2019-2024) & (K Units)

Table 13. Global Drugs for the Treatment of Refractory Gout Sale Market Share by Application (2019-2024)

Table 14. Global Drugs for the Treatment of Refractory Gout Revenue by Application (2019-2024) & (\$ million)

Table 15. Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Application (2019-2024)

Table 16. Global Drugs for the Treatment of Refractory Gout Sale Price by Application (2019-2024) & (US\$/Unit)

Table 17. Global Drugs for the Treatment of Refractory Gout Sales by Company (2019-2024) & (K Units)

Table 18. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Company (2019-2024)

Table 19. Global Drugs for the Treatment of Refractory Gout Revenue by Company (2019-2024) & (\$ millions)

Table 20. Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Company (2019-2024)

Table 21. Global Drugs for the Treatment of Refractory Gout Sale Price by Company (2019-2024) & (US\$/Unit)

Table 22. Key Manufacturers Drugs for the Treatment of Refractory Gout Producing

Area Distribution and Sales Area

Table 23. Players Drugs for theTreatment of Refractory Gout Products Offered

Table 24. Drugs for theTreatment of Refractory Gout Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

Table 25. New Products and Potential Entrants

Table 26. Market M&A Activity & Strategy

Table 27. Global Drugs for theTreatment of Refractory Gout Sales by Geographic Region (2019-2024) & (K Units)

Table 28. Global Drugs for theTreatment of Refractory Gout Sales Market Share Geographic Region (2019-2024)

Table 29. Global Drugs for theTreatment of Refractory Gout Revenue by Geographic Region (2019-2024) & (\$ millions)

Table 30. Global Drugs for theTreatment of Refractory Gout Revenue Market Share by Geographic Region (2019-2024)

Table 31. Global Drugs for theTreatment of Refractory Gout Sales by Country/Region (2019-2024) & (K Units)

Table 32. Global Drugs for theTreatment of Refractory Gout Sales Market Share by Country/Region (2019-2024)

Table 33. Global Drugs for theTreatment of Refractory Gout Revenue by Country/Region (2019-2024) & (\$ millions)

Table 34. Global Drugs for theTreatment of Refractory Gout Revenue Market Share by Country/Region (2019-2024)

Table 35. Americas Drugs for theTreatment of Refractory Gout Sales by Country (2019-2024) & (K Units)

Table 36. Americas Drugs for theTreatment of Refractory Gout Sales Market Share by Country (2019-2024)

Table 37. Americas Drugs for theTreatment of Refractory Gout Revenue by Country (2019-2024) & (\$ millions)

Table 38. Americas Drugs for theTreatment of Refractory Gout Sales byType (2019-2024) & (K Units)

Table 39. Americas Drugs for theTreatment of Refractory Gout Sales by Application (2019-2024) & (K Units)

Table 40. APAC Drugs for theTreatment of Refractory Gout Sales by Region (2019-2024) & (K Units)

Table 41. APAC Drugs for theTreatment of Refractory Gout Sales Market Share by Region (2019-2024)

Table 42. APAC Drugs for theTreatment of Refractory Gout Revenue by Region (2019-2024) & (\$ millions)

Table 43. APAC Drugs for theTreatment of Refractory Gout Sales byType (2019-2024)

& (K Units)

Table 44. APAC Drugs for theTreatment of Refractory Gout Sales by Application (2019-2024) & (K Units)

Table 45. Europe Drugs for theTreatment of Refractory Gout Sales by Country (2019-2024) & (K Units)

Table 46. Europe Drugs for theTreatment of Refractory Gout Revenue by Country (2019-2024) & (\$ millions)

Table 47. Europe Drugs for theTreatment of Refractory Gout Sales byType (2019-2024) & (K Units)

Table 48. Europe Drugs for theTreatment of Refractory Gout Sales by Application (2019-2024) & (K Units)

Table 49. Middle East & Africa Drugs for theTreatment of Refractory Gout Sales by Country (2019-2024) & (K Units)

Table 50. Middle East & Africa Drugs for theTreatment of Refractory Gout Revenue Market Share by Country (2019-2024)

Table 51. Middle East & Africa Drugs for theTreatment of Refractory Gout Sales byType (2019-2024) & (K Units)

Table 52. Middle East & Africa Drugs for theTreatment of Refractory Gout Sales by Application (2019-2024) & (K Units)

Table 53. Key Market Drivers & Growth Opportunities of Drugs for theTreatment of Refractory Gout

Table 54. Key Market Challenges & Risks of Drugs for theTreatment of Refractory Gout

Table 55. Key IndustryTrends of Drugs for theTreatment of Refractory Gout

Table 56. Drugs for theTreatment of Refractory Gout Raw Material

Table 57. Key Suppliers of Raw Materials

Table 58. Drugs for theTreatment of Refractory Gout Distributors List

Table 59. Drugs for theTreatment of Refractory Gout Customer List

Table 60. Global Drugs for theTreatment of Refractory Gout SalesForecast by Region (2025-2030) & (K Units)

Table 61. Global Drugs for theTreatment of Refractory Gout RevenueForecast by Region (2025-2030) & (\$ millions)

Table 62. Americas Drugs for theTreatment of Refractory Gout SalesForecast by Country (2025-2030) & (K Units)

Table 63. Americas Drugs for theTreatment of Refractory Gout Annual RevenueForecast by Country (2025-2030) & (\$ millions)

Table 64. APAC Drugs for theTreatment of Refractory Gout SalesForecast by Region (2025-2030) & (K Units)

Table 65. APAC Drugs for theTreatment of Refractory Gout Annual RevenueForecast by Region (2025-2030) & (\$ millions)

Table 66. Europe Drugs for theTreatment of Refractory Gout SalesForecast by Country (2025-2030) & (K Units)

Table 67. Europe Drugs for theTreatment of Refractory Gout RevenueForecast by Country (2025-2030) & (\$ millions)

Table 68. Middle East & Africa Drugs for theTreatment of Refractory Gout SalesForecast by Country (2025-2030) & (K Units)

Table 69. Middle East & Africa Drugs for theTreatment of Refractory Gout RevenueForecast by Country (2025-2030) & (\$ millions)

Table 70. Global Drugs for theTreatment of Refractory Gout SalesForecast byType (2025-2030) & (K Units)

Table 71. Global Drugs for theTreatment of Refractory Gout RevenueForecast byType (2025-2030) & (\$ millions)

Table 72. Global Drugs for theTreatment of Refractory Gout SalesForecast by Application (2025-2030) & (K Units)

Table 73. Global Drugs for theTreatment of Refractory Gout RevenueForecast by Application (2025-2030) & (\$ millions)

Table 74. Roche Basic Information, Drugs for theTreatment of Refractory Gout Manufacturing Base, Sales Area and Its Competitors

Table 75. Roche Drugs for theTreatment of Refractory Gout Product Portfolios and Specifications

Table 76. Roche Drugs for theTreatment of Refractory Gout Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 77. Roche Main Business

Table 78. Roche Latest Developments

Table 79. Biogen Basic Information, Drugs for theTreatment of Refractory Gout Manufacturing Base, Sales Area and Its Competitors

Table 80. Biogen Drugs for theTreatment of Refractory Gout Product Portfolios and Specifications

Table 81. Biogen Drugs for theTreatment of Refractory Gout Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 82. Biogen Main Business

Table 83. Biogen Latest Developments

Table 84.Fresenius Kabi Basic Information, Drugs for theTreatment of Refractory Gout Manufacturing Base, Sales Area and Its Competitors

Table 85.Fresenius Kabi Drugs for theTreatment of Refractory Gout Product Portfolios and Specifications

Table 86.Fresenius Kabi Drugs for theTreatment of Refractory Gout Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 87.Fresenius Kabi Main Business

Table 88. Fresenius Kabi Latest Developments

Table 89. Novartis Basic Information, Drugs for the Treatment of Refractory Gout Manufacturing Base, Sales Area and Its Competitors

Table 90. Novartis Drugs for the Treatment of Refractory Gout Product Portfolios and Specifications

Table 91. Novartis Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 92. Novartis Main Business

Table 93. Novartis Latest Developments

Table 94. Sobi Basic Information, Drugs for the Treatment of Refractory Gout Manufacturing Base, Sales Area and Its Competitors

Table 95. Sobi Drugs for the Treatment of Refractory Gout Product Portfolios and Specifications

Table 96. Sobi Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 97. Sobi Main Business

Table 98. Sobi Latest Developments

Table 99. Kiniksa Pharmaceuticals Basic Information, Drugs for the Treatment of Refractory Gout Manufacturing Base, Sales Area and Its Competitors

Table 100. Kiniksa Pharmaceuticals Drugs for the Treatment of Refractory Gout Product Portfolios and Specifications

Table 101. Kiniksa Pharmaceuticals Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 102. Kiniksa Pharmaceuticals Main Business

Table 103. Kiniksa Pharmaceuticals Latest Developments

Table 104. Pfizer Basic Information, Drugs for the Treatment of Refractory Gout Manufacturing Base, Sales Area and Its Competitors

Table 105. Pfizer Drugs for the Treatment of Refractory Gout Product Portfolios and Specifications

Table 106. Pfizer Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 107. Pfizer Main Business

Table 108. Pfizer Latest Developments

Table 109. Amgen Basic Information, Drugs for the Treatment of Refractory Gout Manufacturing Base, Sales Area and Its Competitors

Table 110. Amgen Drugs for the Treatment of Refractory Gout Product Portfolios and Specifications

Table 111. Amgen Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 112. Amgen Main Business

Table 113. Amgen Latest Developments

Table 114. Horizon Therapeutics Basic Information, Drugs for the Treatment of Refractory Gout Manufacturing Base, Sales Area and Its Competitors

Table 115. Horizon Therapeutics Drugs for the Treatment of Refractory Gout Product Portfolios and Specifications

Table 116. Horizon Therapeutics Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 117. Horizon Therapeutics Main Business

Table 118. Horizon Therapeutics Latest Developments

Table 119. Qilu Pharmaceutical Basic Information, Drugs for the Treatment of Refractory Gout Manufacturing Base, Sales Area and Its Competitors

Table 120. Qilu Pharmaceutical Drugs for the Treatment of Refractory Gout Product Portfolios and Specifications

Table 121. Qilu Pharmaceutical Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 122. Qilu Pharmaceutical Main Business

Table 123. Qilu Pharmaceutical Latest Developments

Table 124. Hanwha Chemical Basic Information, Drugs for the Treatment of Refractory Gout Manufacturing Base, Sales Area and Its Competitors

Table 125. Hanwha Chemical Drugs for the Treatment of Refractory Gout Product Portfolios and Specifications

Table 126. Hanwha Chemical Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 127. Hanwha Chemical Main Business

Table 128. Hanwha Chemical Latest Developments

Table 129. Bio-Thera Solutions Basic Information, Drugs for the Treatment of Refractory Gout Manufacturing Base, Sales Area and Its Competitors

Table 130. Bio-Thera Solutions Drugs for the Treatment of Refractory Gout Product Portfolios and Specifications

Table 131. Bio-Thera Solutions Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 132. Bio-Thera Solutions Main Business

Table 133. Bio-Thera Solutions Latest Developments

Table 134. Zhuhai Livzon Biotechnology Basic Information, Drugs for the Treatment of Refractory Gout Manufacturing Base, Sales Area and Its Competitors

Table 135. Zhuhai Livzon Biotechnology Drugs for the Treatment of Refractory Gout Product Portfolios and Specifications

Table 136. Zhuhai Livzon Biotechnology Drugs for the Treatment of Refractory Gout

Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 137. Zhuhai Livzon Biotechnology Main Business

Table 138. Zhuhai Livzon Biotechnology Latest Developments

Table 139. Sandoz Basic Information, Drugs for the Treatment of Refractory Gout Manufacturing Base, Sales Area and Its Competitors

Table 140. Sandoz Drugs for the Treatment of Refractory Gout Product Portfolios and Specifications

Table 141. Sandoz Drugs for the Treatment of Refractory Gout Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 142. Sandoz Main Business

Table 143. Sandoz Latest Developments

LIST OFFIGURES

Figure 1. Picture of Drugs for the Treatment of Refractory Gout

Figure 2. Drugs for the Treatment of Refractory Gout Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Drugs for the Treatment of Refractory Gout Sales Growth Rate 2019-2030 (K Units)

Figure 7. Global Drugs for the Treatment of Refractory Gout Revenue Growth Rate 2019-2030 (\$ millions)

Figure 8. Drugs for the Treatment of Refractory Gout Sales by Geographic Region (2019, 2023 & 2030) & (\$ millions)

Figure 9. Drugs for the Treatment of Refractory Gout Sales Market Share by Country/Region (2023)

Figure 10. Drugs for the Treatment of Refractory Gout Sales Market Share by Country/Region (2019, 2023 & 2030)

Figure 11. Product Picture of Interleukin Inhibitors

Figure 12. Product Picture of Tumor Necrosis Factor Inhibitors

Figure 13. Product Picture of PEGylated Recombinant Uricase

Figure 14. Product Picture of Other

Figure 15. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Type in 2023

Figure 16. Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Type (2019-2024)

- Figure 17. Drugs for theTreatment of Refractory Gout Consumed in Hospital and Clinic
- Figure 18. Global Drugs for theTreatment of Refractory Gout Market: Hospital and Clinic (2019-2024) & (K Units)
- Figure 19. Drugs for theTreatment of Refractory Gout Consumed in Retail Pharmacies
- Figure 20. Global Drugs for theTreatment of Refractory Gout Market: Retail Pharmacies (2019-2024) & (K Units)
- Figure 21. Drugs for theTreatment of Refractory Gout Consumed in Other
- Figure 22. Global Drugs for theTreatment of Refractory Gout Market: Other (2019-2024) & (K Units)
- Figure 23. Global Drugs for theTreatment of Refractory Gout Sale Market Share by Application (2023)
- Figure 24. Global Drugs for theTreatment of Refractory Gout Revenue Market Share by Application in 2023
- Figure 25. Drugs for theTreatment of Refractory Gout Sales by Company in 2023 (K Units)
- Figure 26. Global Drugs for theTreatment of Refractory Gout Sales Market Share by Company in 2023
- Figure 27. Drugs for theTreatment of Refractory Gout Revenue by Company in 2023 (\$ millions)
- Figure 28. Global Drugs for theTreatment of Refractory Gout Revenue Market Share by Company in 2023
- Figure 29. Global Drugs for theTreatment of Refractory Gout Sales Market Share by Geographic Region (2019-2024)
- Figure 30. Global Drugs for theTreatment of Refractory Gout Revenue Market Share by Geographic Region in 2023
- Figure 31. Americas Drugs for theTreatment of Refractory Gout Sales 2019-2024 (K Units)
- Figure 32. Americas Drugs for theTreatment of Refractory Gout Revenue 2019-2024 (\$ millions)
- Figure 33. APAC Drugs for theTreatment of Refractory Gout Sales 2019-2024 (K Units)
- Figure 34. APAC Drugs for theTreatment of Refractory Gout Revenue 2019-2024 (\$ millions)
- Figure 35. Europe Drugs for theTreatment of Refractory Gout Sales 2019-2024 (K Units)
- Figure 36. Europe Drugs for theTreatment of Refractory Gout Revenue 2019-2024 (\$ millions)
- Figure 37. Middle East & Africa Drugs for theTreatment of Refractory Gout Sales 2019-2024 (K Units)
- Figure 38. Middle East & Africa Drugs for theTreatment of Refractory Gout Revenue

2019-2024 (\$ millions)

Figure 39. Americas Drugs for theTreatment of Refractory Gout Sales Market Share by Country in 2023

Figure 40. Americas Drugs for theTreatment of Refractory Gout Revenue Market Share by Country (2019-2024)

Figure 41. Americas Drugs for theTreatment of Refractory Gout Sales Market Share byType (2019-2024)

Figure 42. Americas Drugs for theTreatment of Refractory Gout Sales Market Share by Application (2019-2024)

Figure 43. United States Drugs for theTreatment of Refractory Gout Revenue Growth 2019-2024 (\$ millions)

Figure 44. Canada Drugs for theTreatment of Refractory Gout Revenue Growth 2019-2024 (\$ millions)

Figure 45. Mexico Drugs for theTreatment of Refractory Gout Revenue Growth 2019-2024 (\$ millions)

Figure 46. Brazil Drugs for theTreatment of Refractory Gout Revenue Growth 2019-2024 (\$ millions)

Figure 47. APAC Drugs for theTreatment of Refractory Gout Sales Market Share by Region in 2023

Figure 48. APAC Drugs for theTreatment of Refractory Gout Revenue Market Share by Region (2019-2024)

Figure 49. APAC Drugs for theTreatment of Refractory Gout Sales Market Share byType (2019-2024)

Figure 50. APAC Drugs for theTreatment of Refractory Gout Sales Market Share by Application (2019-2024)

Figure 51. China Drugs for theTreatment of Refractory Gout Revenue Growth 2019-2024 (\$ millions)

Figure 52. Japan Drugs for theTreatment of Refractory Gout Revenue Growth 2019-2024 (\$ millions)

Figure 53. South Korea Drugs for theTreatment of Refractory Gout Revenue Growth 2019-2024 (\$ millions)

Figure 54. Southeast Asia Drugs for theTreatment of Refractory Gout Revenue Growth 2019-2024 (\$ millions)

Figure 55. India Drugs for theTreatment of Refractory Gout Revenue Growth 2019-2024 (\$ millions)

Figure 56. Australia Drugs for theTreatment of Refractory Gout Revenue Growth 2019-2024 (\$ millions)

Figure 57. ChinaTaiwan Drugs for theTreatment of Refractory Gout Revenue Growth 2019-2024 (\$ millions)

Figure 58. Europe Drugs for theTreatment of Refractory Gout Sales Market Share by Country in 2023

Figure 59. Europe Drugs for theTreatment of Refractory Gout Revenue Market Share by Country (2019-2024)

Figure 60. Europe Drugs for theTreatment of Refractory Gout Sales Market Share byType (2019-2024)

Figure 61. Europe Drugs for theTreatment of Refractory Gout Sales Market Share by Application (2019-2024)

Figure 62. Germany Drugs for theTreatment of Refractory Gout Revenue Growth 2019-2024 (\$ millions)

Figure 63.France Drugs for theTreatment of Refractory Gout Revenue Growth 2019-2024 (\$ millions)

Figure 64. UK Drugs for theTreatment of Refractory Gout Revenue Growth 2019-2024 (\$ millions)

Figure 65. Italy Drugs for theTreatment of Refractory Gout Revenue Growth 2019-2024 (\$ millions)

Figure 66. Russia Drugs for theTreatment of Refractory Gout Revenue Growth 2019-2024 (\$ millions)

Figure 67. Middle East & Africa Drugs for theTreatment of Refractory Gout Sales Market Share by Country (2019-2024)

Figure 68. Middle East & Africa Drugs for theTreatment of Refractory Gout Sales Market Share byType (2019-2024)

Figure 69. Middle East & Africa Drugs for theTreatment of Refractory Gout Sales Market Share by Application (2019-2024)

Figure 70. Egypt Drugs for theTreatment of Refractory Gout Revenue Growth 2019-2024 (\$ millions)

Figure 71. South Africa Drugs for theTreatment of Refractory Gout Revenue Growth 2019-2024 (\$ millions)

Figure 72. Israel Drugs for theTreatment of Refractory Gout Revenue Growth 2019-2024 (\$ millions)

Figure 73.Turkey Drugs for theTreatment of Refractory Gout Revenue Growth 2019-2024 (\$ millions)

Figure 74. GCC Countries Drugs for theTreatment of Refractory Gout Revenue Growth 2019-2024 (\$ millions)

Figure 75. Manufacturing Cost Structure Analysis of Drugs for theTreatment of Refractory Gout in 2023

Figure 76. Manufacturing Process Analysis of Drugs for theTreatment of Refractory Gout

Figure 77. Industry Chain Structure of Drugs for theTreatment of Refractory Gout

Figure 78. Channels of Distribution

Figure 79. Global Drugs for the Treatment of Refractory Gout Sales Market Forecast by Region (2025-2030)

Figure 80. Global Drugs for the Treatment of Refractory Gout Revenue Market Share Forecast by Region (2025-2030)

Figure 81. Global Drugs for the Treatment of Refractory Gout Sales Market Share Forecast by Type (2025-2030)

Figure 82. Global Drugs for the Treatment of Refractory Gout Revenue Market Share Forecast by Type (2025-2030)

Figure 83. Global Drugs for the Treatment of Refractory Gout Sales Market Share Forecast by Application (2025-2030)

Figure 84. Global Drugs for the Treatment of Refractory Gout Revenue Market Share Forecast by Application (2025-2030)

I would like to order

Product name: Global Drugs for the Treatment of Refractory Gout Market Growth 2024-2030

Product link: <https://marketpublishers.com/r/GE52568B6238EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GE52568B6238EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970